Midwest Biomedical Accelerator Consortium: MBArC

中西部生物医学加速器联盟：MBArC

基本信息

批准号：
10022343
负责人：
William P Fay
金额：
$ 98.1万
依托单位：
UNIVERSITY OF MISSOURI-COLUMBIA
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-23 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10022343
关键词：
Active Learning Address Award Awareness Biological Biomedical Engineering Biomedical Research Biomedical Technology Businesses Cities Clinical Clinical and Translational Science Awards Collaborations Complex Coupling Data Development Devices Diagnosis Economic Development Entrepreneurship Evaluation Research Faculty Failure Fostering Funding Funding Agency Geography Goals Health Infrastructure Institution Investments Kansas Laboratories Laboratory Research Leadership Learning Legal Medical Medical center Mentors Mentorship Methodology Midwestern United States Missouri Modeling Pathway interactions Patient Care Pharmaceutical Preparations Phase Population Postdoctoral Fellow Process Public Domains Research Research Personnel Resource Sharing Resources Rewards Risk Science Scientist Societies Students System Talents Technology Technology Transfer Training Translating Translational Research Translations United States National Institutes of Health Universities Work base bench to bedside biological research biomedical scientist burden of illness citizen science commercialization frontier human disease improved innovation inter-institutional member method development novel novel strategies prevent programs recruit working group

项目摘要

Project Summary/Abstract The ultimate goal of biomedical research is to create new devices, drugs, and technologies that prevent, diagnose, and treat human diseases. Like scientific discovery, biomedical technology commercialization is complex and requires mentorship, resources, collaboration, and risk. However, several hurdles limit commercialization of promising laboratory discoveries, including 1) lack of awareness by academicians that commercialization is an option, 2) concerns that commercialization efforts delay academic advancement, and 3) failure to connect investigators with the collaborators and experts necessary to complete the commercialization process. The objective of this Research Evaluation and Commercialization Hub (REACH) proposal is to establish a partnership between the University of Missouri-Columbia (MU) and the University of Kansas Medical Center (KUMC) that will promote academic entrepreneurship and commercialization. To this collaboration MU brings its outstanding biomedical and bioengineering research programs and its vibrant track record of participation in the Coulter Translational Research Partnership Award program. KUMC provides its exceptional biomedical research programs and Frontiers, its NIH Clinical and Translational Science Award (CTSA). In addition, each institution has existing partnerships that strengthen and extend the alliance - i.e. 1) MU with University of Missouri state system universities in Kansas City, St. Louis, and Rolla; and 2) KUMC with the Kansas Idea Network of Biomedical Research Excellence (K-INBRE) and the Sustainable Heartland Accelerator Regional Partnership Hub (SHARPhub). The leadership team of this network, entitled the Midwest Biomedical Accelerator Consortium (MBArC), will employ the following strategies to increase biomedical research commercialization: 1) leverage MBArC’s geographic and institutional scope to develop strategic partnerships that invite scientists to engage in technology transfer and commercialization, 2) give academicians the training and resources needed to validate the clinical and commercial feasibility of their innovations, 3) provide researchers with funding and mentorship to complete product definition studies and attract follow- on funding, and 4) offer experiential learning opportunities in biomedical innovation and entrepreneurship. This initiative will build on existing programs in outstanding institutions to increase health-related business development, including small businesses, in Missouri, Kansas, and adjoining states. The MBArC REACH Hub will promote commercialization of novel scientific discoveries and establish a sustainable infrastructure to translate scientific discoveries into commercial products that prevent and treat high-burden diseases afflicting the US population.

项目概要/摘要生物医学研究的最终目标是创造新的设备、药物和技术预防、诊断和治疗人类疾病，如科学发现、生物医学技术。商业化是复杂的，需要指导、资源、协作和风险。然而，有几个障碍限制了有前途的实验室发现的商业化，包括 1) 学术界缺乏对商业化是一种选择的认识，2) 担心商业化努力延迟了学术进步，3）未能联系研究人员与完成商业化过程所需的合作者和专家。该研究评估和商业化中心 (REACH) 提案的目标是密苏里大学哥伦比亚分校 (MU) 与密苏里大学哥伦比亚分校建立合作伙伴关系堪萨斯医学中心 (KUMC) 将促进学术创业和 MU 为此次合作带来了其出色的生物医学和生物工程技术。研究项目及其参与库尔特翻译项目的活跃记录研究合作奖计划提供卓越的生物医学研究。计划和前沿，其 NIH 临床和转化科学奖 (CTSA)。每个机构都有现有的伙伴关系来加强和扩展联盟 - 即 1) MU 与堪萨斯城、圣路易斯和罗拉的密苏里大学州立系统大学；2) KUMC 与堪萨斯生物医学卓越研究理念网络 (K-INBRE) 和可持续发展 Heartland 加速器区域合作中心 (SHARPhub) 的领导团队。名为中西部生物医学加速器联盟（MBArC）的网络将采用以下策略可提高生物医学研究商业化：1) 利用 MBArC 发展战略伙伴关系的地理和机构范围，邀请科学家从事技术转让和商业化，2）为院士提供培训和验证其创新的临床和商业可行性所需的资源，3) 提供研究人员获得资金和指导来完成产品定义研究并吸引追随者资金，以及 4）提供生物医学创新的体验式学习机会该举措将以优秀机构的现有计划为基础，以促进创业。促进密苏里州、堪萨斯州与健康相关的企业发展，包括小型企业， MBArC REACH 中心将促进新颖科学的商业化。发现并建立可持续的基础设施，将科学发现转化为预防和治疗困扰美国人口的高负担疾病的商业产品。